Press release
Chronic Refractory Cough Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Refractory Cough Treatment Landscape. Click here to read more @ Chronic Refractory Cough Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Refractory Cough Pipeline Report
* On 13 August 2025, Nocion Therapeutics announced a phase 2b study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
* DelveInsight's Chronic Refractory Cough pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Refractory Cough treatment.
* The leading Chronic Refractory Cough Companies such as GSK, Trevi Therapeutics, Patara Pharma, Vyne Therapeutics Inc., Nerre Therapeutics Ltd., Shionogi, Avalo Therapeutics, Inc. and others.
* Promising Chronic Refractory Cough Pipeline Therapies such as BLU-5937, Gefapixant, PA101, Gefapixant, Orvepitant Maleate, FP01, S-600918 and others.
Stay informed about the cutting-edge advancements in Chronic Refractory Cough Treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Chronic Refractory Cough Clinical Trials Assessment [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Refractory Cough Emerging Drugs Profile
* GSK5464714: GSK
Camlipixant, also known as BLU-5937 or GSK-5464714, is an orally available small molecule developed by BELLUS Health, a subsidiary of GSK. It is a P2X3 receptor antagonist targeting chronic cough and other related disorders. In a phase 2b parallel group study, patients with =25 coughs per hour who received 50 mg or 200 mg of camlipixant twice daily had a 34% greater reduction in 24-hour cough frequency compared to placebo. Approximately 5% of patients on any of the three camlipixant doses experienced dysgeusia (taste disturbance), which is lower than other P2X3 antagonists. GSK recently acquired BELLUS Health, the company developing camlipixant, for $2 billion. GSK cited camlipixant's potential to be a best-in-class treatment for RCC with significant sales potential. Camlipixant is currently in Phase III stage of clinical trial evaluation for the treatment of Chronic Refractory Cough.
The Chronic Refractory Cough pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.
* Chronic Refractory Cough Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.
Get a detailed analysis of the latest innovations in the Chronic Refractory Cough pipeline. Explore DelveInsight's expert-driven report today! @ Chronic Refractory Cough Unmet Needs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Refractory Cough Companies
GSK, Trevi Therapeutics, Patara Pharma, Vyne Therapeutics Inc., Nerre Therapeutics Ltd., Shionogi, Avalo Therapeutics, Inc. and others.
Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Chronic Refractory Cough Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Chronic Refractory Cough Treatment by visiting our website. Stay informed about how we're transforming the future of Respiratory Disease @ Chronic Refractory Cough Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Refractory Cough Pipeline Report
* Coverage- Global
* Chronic Refractory Cough Companies- GSK, Trevi Therapeutics, Patara Pharma, Vyne Therapeutics Inc., Nerre Therapeutics Ltd., Shionogi, Avalo Therapeutics, Inc. and others.
* Chronic Refractory Cough Pipeline Therapies- BLU-5937, Gefapixant, PA101, Gefapixant, Orvepitant Maleate, FP01, S-600918 and others.
* Chronic Refractory Cough Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Refractory Cough Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Chronic Refractory Cough Pipeline on our website @ Chronic Refractory Cough Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Chronic Refractory Cough: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Refractory Cough- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK5464714: GSK
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Chronic Refractory Cough Key Companies
* Chronic Refractory Cough Key Products
* Chronic Refractory Cough- Unmet Needs
* Chronic Refractory Cough- Market Drivers and Barriers
* Chronic Refractory Cough- Future Perspectives and Conclusion
* Chronic Refractory Cough Analyst Views
* Chronic Refractory Cough Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-refractory-cough-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Refractory Cough Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4155066 • Views: …
More Releases from ABNewswire
Influenza Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, M …
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment.
Influenza Pipeline Summary
DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza;…
PCSK9 Inhibitors Market Landscape: Clinical Pipeline, Competitive Strategies, an …
DelveInsight's PCSK9 Inhibitors Market Report highlights strong growth potential, with the 7MM market projected to expand significantly by 2034 from USD 2B in 2023. The U.S. leads with ~USD 900M. Key players include Sanofi, Regeneron, Amgen, AstraZeneca, LIB Therapeutics, Merck, Novartis, Alnylam, Aqur Biosciences, and CiVi Biopharma. Current leaders PRALUENT and REPATHA dominate, while pipeline assets like LIB003 and MK-0616 signal the next wave of innovation.
DelveInsight's comprehensive [https://www.delveinsight.com/report-store/pcsk9-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report, provides…
Bronchiectasis Treatment Landscape: FDA Approves BRINSUPRI, First Disease-Modify …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of BRINSUPRI (brensocatib) by Insmed Incorporated (NASDAQ: INSM). This landmark approval marks the first disease-specific therapy for bronchiectasis, offering new hope for over one million patients suffering from this chronic, progressive lung disease characterized by irreversible bronchial airway dilation and impaired mucociliary function.
Key Bronchiectasis Market Highlights
*
BRINSUPRI's approval is expected to be a key bronchiectasis market driver,…
Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba) by Precigen, Inc. (NASDAQ: PGEN). This landmark approval marks the first FDA-approved therapy for recurrent respiratory papillomatosis in history, offering unprecedented hope for thousands of patients suffering from this rare and debilitating condition caused by human papillomavirus infection.
Key Recurrent Respiratory Papillomatosis Market Highlights
*
PAPZIMEOS approval represents a paradigm shift in the recurrent respiratory…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
